Literature DB >> 30421142

Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy.

Krzysztof Adamowicz1, Justyna Janiszewska2, Monika Lichodziejewska-Niemierko2,3.   

Abstract

The purpose of the study was to assess the impact of cancer knowledge and patient's lifestyle on QOL and the relationship between QOL and various environmental factors in patients with non-small-cell lung cancer treated with chemotherapy. The study group consisted of 129 patients with metastatic lung cancer patients treated between May 2010 and December 2015 in two centres. The knowledge of cancer and their lifestyle was rated by method of diagnostic survey, using the Behavioral Health Inventory IZZ by Prof. Juczyński. We sought factors affecting to response to treatment, overall survival and quality of life. The general level of knowledge of cancer and the level of health behaviours was low. Ninety percent of lung cancer patients were smokers. The average age of the study group was 64 years. Eighty-nine patients received chemotherapy with cisplatin, 28 schemes containing carboplatin, 6 inhibitors of EGFR tyrosine kinase, and 6 vinorelbine or gemcitabine monotherapy. Complete regression was observed in 2 patients, partial response in 33 patients (26%), stable disease in 51 (40%) and 54 (42%) patients had progression. In multivariate analysis, significant effects on survival were performance status, schemes of treatment and response to treatment. Quality of life before and after treatment did not differ from each other. We found impact on quality of life: performance status, response to treatment and knowledge of cancer and lifestyle. The level of knowledge of oncological patients and their lifestyle observed in clinical practice are associated with QOL.

Entities:  

Keywords:  Chemotherapy; Knowledge of cancer; Lung cancer; Quality of life; Treatment outcomes

Mesh:

Substances:

Year:  2020        PMID: 30421142     DOI: 10.1007/s13187-018-1444-3

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  10 in total

Review 1.  Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials.

Authors:  Everardo D Saad; Krzysztof Adamowicz; Artur Katz; Jacek Jassem
Journal:  Cancer Treat Rev       Date:  2012-03-23       Impact factor: 12.111

2.  Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials.

Authors:  Krzysztof Adamowicz; Jacek Jassem; Artur Katz; Everardo D Saad
Journal:  Cancer Treat Rev       Date:  2011-07-31       Impact factor: 12.111

3.  The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.

Authors: 
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

4.  Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.

Authors:  Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia
Journal:  Lancet Oncol       Date:  2013-12-05       Impact factor: 41.316

5.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Authors:  L B Saltz; J V Cox; C Blanke; L S Rosen; L Fehrenbacher; M J Moore; J A Maroun; S P Ackland; P K Locker; N Pirotta; G L Elfring; L L Miller
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

6.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study.

Authors:  E Aranda; M Valladares; M Martinez-Villacampa; M Benavides; A Gomez; B Massutti; E Marcuello; M Constenla; J C Cámara; A Carrato; R Dueñas; M Reboredo; M Navarro; E Díaz-Rubio
Journal:  Ann Oncol       Date:  2008-08-20       Impact factor: 32.976

Review 8.  Effect of psychosocial interventions on outcomes of patients with colorectal cancer: a review of the literature.

Authors:  Lim Siew Hoon; Chan Wai Chi Sally; He Hong-Gu
Journal:  Eur J Oncol Nurs       Date:  2013-06-04       Impact factor: 2.398

9.  Quality of life, anxiety, and depression in Turkish colorectal cancer patients.

Authors:  Ahmet Alacacioglu; Omer Binicier; Ozkan Gungor; Ilhan Oztop; Meliha Dirioz; Ugur Yilmaz
Journal:  Support Care Cancer       Date:  2009-06-25       Impact factor: 3.603

10.  Evaluation of the Impact of Different Types of Health Education on the Adoption and Preservation of Prohealth Attitudes in Preventing Cancer in Juveniles Younger than 18 Years.

Authors:  Krzysztof Adamowicz; Marta Zalewska; Mikołaj Majkowicz; Jan Maciej Zaucha
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

  10 in total
  2 in total

1.  Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis.

Authors:  Jeongok Park; Young Deuk Choi; Kyoungjin Lee; Miae Seo; Ahyoung Cho; Sejeong Lee; Keum-Hee Nam
Journal:  Asia Pac J Oncol Nurs       Date:  2022-04-12

2.  The Importance of Social Support, Optimism and Resilience on the Quality of Life of Cancer Patients.

Authors:  Iván Ruiz-Rodríguez; Isabel Hombrados-Mendieta; Anabel Melguizo-Garín; María José Martos-Méndez
Journal:  Front Psychol       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.